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ABSTRACT 
Non-invasive biomarkers for early pancreatic ductal adenocarcinoma (PDAC) diagnosis and 
disease risk stratification are greatly needed. We conducted a nested case-control study within 
the Prospective Investigation into Cancer and Nutrition (EPIC) cohort to evaluate pre-
diagnostic microRNAs (miRs) as biomarkers of subsequent PDAC risk. A panel of eight 
miRs (miR-10a, -10b, -21-3p, -21-5p, -30c, -106b, -155, and -212) based on previous 
evidence from our group was evaluated in 225 microscopically confirmed PDAC cases and 
225 controls matched on center, sex, fasting status, and age/date/time of blood collection. 
MiR levels in pre-diagnostic plasma samples were determined by quantitative RT-PCR. 
Logistic regression was used to model levels and PDAC risk, adjusting for covariates, and to 
estimate area under the receiver operating characteristic curves (AUC). Plasma miR-10b, -21-
5p, -30c and -106b levels were significantly higher in cases diagnosed within 2 yr of blood 
collection compared to matched controls (all P-values <0.04). Based on adjusted logistic 
regression models, levels for six miRs (miR-10a, -10b, -21-5p, -30c, -155, and -212) overall, 
and for four miRs (-10a, -10b, -21-5p, and -30c) at shorter follow-up time between blood 
collection and diagnosis (≤5 yr, ≤2 yr), were statistically significantly associated with risk. A 
score based on the panel showed a linear dose-response trend with risk (P-value=0.0006). For 
shorter follow-up (≤5 yr), AUC for the score was 0.73, and for individual miRs ranged from 
0.73 (miR-212) to 0.79 (miR-21-p).  
 
 
 
 
Novelty and Impact 
In this first prospective study of microRNAs and pancreatic cancer, samples collected ≤2 yr 
pre-diagnosis showed elevated plasma levels of miR-10b, miR-21-5p, miR-30c, and miR-
106b compared to controls. In multivariable models, levels of miR-10a, miR-10b, miR-21-5p, 
and miR-30c showed significant associations with subsequent risk; with stronger associations 
for miR-21-5p and miR-30c ≤2 or ≤5 yr pre-diagnosis. Plasma microRNAs might serve as 
biomarkers of pancreatic cancer risk and (with other markers) in screening high-risk 
populations.
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INTRODUCTION 
Pancreatic cancer is the third leading cause of cancer death in men and women combined in 
the U.S., and, due to late diagnosis and limited treatment options, has the worst prognosis of 
all cancers (1;2). Approximately 95% of pancreatic cancers are ductal adenocarcinomas 
(PDAC) which have been projected to become the second leading cause of cancer death by 
2030 (3). Little is understood in terms of preventable risk factors, and known risk factors 
including common genetic variants are inadequate for risk stratification or early diagnosis; 
thus, a top research priority in PDAC research has been to identify non-invasive early markers 
of risk.  
 
MicroRNAs (miRs) are small non-coding RNAs consisting of 18-25 nucleotides that function 
through several mechanisms. In general, miRs target specific mRNAs for translational 
repression or degradation, and thus regulate important biological processes including cell 
proliferation, survival, invasion and metastasis (4-7).  In comparison with the normal 
pancreas, numerous miRs are overexpressed in PDAC, including miR-21, -10b, -30c, -196a, -
203, -155, -101b, -205, -210, -221, -222, -223, -486, -744, and -10a (5;8-21). Both miR-10b 
and miR-21 are frequently up-regulated in PDAC, where the presence of high levels of each 
of these miRs has been associated with lower patient survival and responsiveness to 
gemcitabine (9;11;14;19). Moreover, miR-10b enhances the pro-metastatic actions of EGF 
and TGF-β (5).  
 
We selected the miRs examined in the present study because, with the exception of miR-21-
3p, they are all overexpressed in PDAC and may contribute to PDAC progression and/or 
metastasis (5;8-22). We chose to include miR-21-3p which originates from the opposite arm 
of the same pre-miR as miR-21-5p that is recognized as an oncogenic miR (OncomiR) in 
PDAC (10;11), and because miR-21-3p also may have oncogenic properties (23;24). In the 
present nested study of pre-diagnostic plasma samples from 225 PDAC cases and 225 
matched controls from the EPIC cohort, we evaluated relative expression of a panel of eight 
miRs (miR-10a, miR-10b, miR-21-3p, miR-21-5p, miR-30c, miR-106b, miR-155, and miR-
212) and PDAC risk, adjusting for known risk factors and potential confounders, as well as 
examination of risk estimates by follow-up time between blood collection and PDAC 
diagnosis. Importantly, miR-10b, -21-5p, -30c, -106b and -155 are expressed in pancreatic 
intra-epithelial neoplasia (PanIN) that are the immediate precursor lesions to PDAC (25-27). 
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METHODS 
Population 
The EPIC cohort includes a total of 521,457 participants (368,010 women and 153,447 men) 
recruited through 23 research centers in 10 European countries including Denmark (Aarhus, 
Copenhagen), France, Germany (Heidelberg, Potsdam), Greece, Italy (Florence, Turin, 
Varese, Naples, Ragusa), The Netherlands (Bilthoven, Utrecht), Norway, Spain (Asturias, 
Granada, Murcia, Navarra, Guipuzcoa), Sweden (Malmo, Umeå) and the United Kingdom 
(Oxford, Cambridge) (28). Most of the participants were enrolled between 1992 and 1998 
between the ages of 35 and 70 years. Participants were recruited from the general population 
residing in the corresponding geographic areas including towns and provinces, except for the 
French cohort which recruited participants from a teacher’s organization health insurance 
program, the cohorts consisting of women attending breast cancer screening programs 
(Utrecht and Florence), parts of the Italian and Spanish cohorts in which participants were 
recruited from among blood donors, and most of the Oxford cohort which recruited mainly 
health-conscious participants, including vegetarians. Eligible participants gave written 
informed consent and completed questionnaires on diet, lifestyle, and medical history at 
baseline. Anthropometric characteristics were measured by interviews except in France and 
Norway, and for the majority of participants from EPIC-Oxford (although the accuracy of 
these self-reported data has been validated (29)), for whom the data were self-reported in the 
lifestyle questionnaires. All participants were cancer-free at the time of data collection, 
including biological samples obtained from approximately 80% of the cohort. Ethical review 
boards from the International Agency for Research on Cancer (IARC) and local centers 
approved the study. In addition, approval for obtaining blood samples from patients at Indiana 
University School of Medicine (IUSM) was granted by the local Institutional Review Board, 
and each participant from whom blood was collected provided written informed consent prior 
to sample collection. 
 
Nested case-control study 
A nested case-control study within EPIC was conducted for the analyses of miR levels and 
PDAC risk. Cohort follow-up started at study enrolment and continued until diagnosis, death 
or last completed follow-up, whichever came first. Cancer incidence in EPIC was determined 
through population-based registries or through active follow-up. Cases had no prior cancer 
history (other than non-melanoma skin cancer) and included first primary adenocarcinoma of 
the pancreas ICD-Oncology third edition codes C25.0-C25.3 and C25.7-C25.9 which did not 
include endocrine or neuroendocrine pancreatic tumors. All PDAC cases selected for this 
study were microscopically confirmed (based on histology of the primary tumor, metastases, 
cytology, or autopsy findings). Control participants were selected randomly among EPIC 
participants who were alive and free of cancer (except non-melanoma skin cancer) at the time 
of diagnosis of each index case and matched to each case based on sex, study center or 
country, age at blood collection (+/- 3 years), date of blood collection (+/- 3 months), time of 
blood collection (+/- 2 hours), fasting status (<3 hours, 3-6 hours, >6 hours after last meal), 
and among women, use of hormones (OC, HRT).  The final sample size was 225 cases and 
225 matched controls. Sweden (Malmo, Umea) did not participate in the study. 
 
miR selection and assay methodology 
EPIC plasma samples were stored in Denmark (-150ºC nitrogen vapour), and at the IARC 
EPIC-biobank for the remaining non-Danish samples (-196ºC liquid nitrogen). Total RNA 
was isolated from plasma samples using Trizol-LS (Life Technologies, Carlsbad, CA, USA) 
and Direct-zol RNA MiniPrep kit (Zymo Research).  cDNA was generated using 10 ng of 
RNA per reaction in conjunction with miR-10a, 10b, -30c, -21-3p, -21-5p, 106b, -155, -212, 
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or -425-5p RT primers and a miR reverse transcription kit (Life Technologies), as previously 
reported (22).  Quantitative PCR (qPCR) was performed using miR Taqman® probes and 
TaqMan Fast Advanced Master Mix (22).  Expression levels for candidate miRs were 
normalized to miR-425-5p, which was expressed at similar levels in all sample types, 
exhibiting <1 cycle threshold (Ct) difference across the samples (22).  After normalization to 
miR-425-5p (ΔCt), the ΔCt values for miRs in controls were averaged and subtracted from 
the ΔCt values of each individual sample (ΔΔCt), and expression levels were calculated using 
the 2
-ΔΔCt
 method (30).   
 
All miR measurements were initially blinded to case-control status. To confirm assay 
reproducibility, samples from seven subjects (4 cases, 3 controls) were re-analyzed with 
similar results for all miRs. Moreover, since the same PCR instrument (ViiA7) and 
methodology were used our current and previous study (22), we compared plasma samples 
from a cohort of normal controls at IUSM with the normal values in the current study 
following data unblinding. In spite of differences between EPIC and IUSM with respect to the 
duration of sample storage, temperature (-150ºC or -196ºC for European samples vs -70ºC for 
American samples), there was remarkable concordance between the two studies with respect 
to ΔCt values in the control samples for each miR (Supplementary Table S1). 
 
In view of the near identical seed sequence for miR-10a and -10b, and the fact that their 
mature forms only differ at a single nucleotide, we next confirmed that our qPCR method 
readily distinguished between miR-10a and -10b (Supplementary Figure S1).  
  
To confirm that miRNA-425-5p is a reliable internal control, following completion of the RT-
qPCR assays and designation of control and PDAC cases, the mean Ct values for miRNA-
425-5p in all 450 EPIC samples were compared with the corresponding miRNA mean Ct 
values for the 225 control subjects and the 225 individuals who were diagnosed with PDAC 
(Supplementary Table S2). There was remarkable uniformity in miRNA-425-5p levels across 
the entire study, validating its utility as an internal control miRNA. 
 
To validate the efficiency of our RNA extraction procedure, we performed a spike-in 
experiment using plasma samples from three normal and three PDAC patients from the IU 
Simon Cancer Center Tissue and Biofluid Bank that were spiked with varying levels of cel-
miRNA-39 (Supplementary Table S3). The mean threshold (Ct) values ± SEM in normal and 
PDAC samples were then determined for cel-miRNA-39, hsa-miRNA-425-5p, hsa-miRNA-
16 or RNU6B, by RT-qPCR. This analysis confirmed the efficiency of our RNA extraction 
procedure and the uniformity of miRNA-425-5p levels even in plasma from non-EPIC 
samples. Moreover, miR-16 and RNU6B levels were fairly uniform across normal and PDAC 
samples. 
 
Danish samples were subjected to a flood in 2011. Therefore, we next evaluated whether miR 
expression for each miR was systematically different between Danish and non-Danish 
samples (31). Among 146 Danish and 79 non-Danish control samples, only two miRs 
(miR21-3p and miR-106b) had lower median expression in Danish samples, but neither 
difference was statistically significant (Wilcoxon rank sum test P-values ≥0.19). In general, 
Danish samples showed little evidence of miR degradation in comparison to non-Danish 
samples. These observations are consistent with the fact that there was no evidence that water 
entered the vials storing the Danish samples, and that miRs are resistant to degradation under 
many conditions, including at least 10 cycles of freeze-thawing (32). 
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Statistical Methods 
Data transformation 
Expression levels for each miR were modelled continuously using log2-transformation to 
facilitate interpretation of results and improve normality of the distributions. Spearman 
correlation coefficients (rs) were used to assess correlations among the un-transformed miRs 
and covariates. A non-parametric Wilcoxon rank sum test was used to compare median 
untransformed miR levels by case-control status and other dichotomous variables. Non-
parametric Kruskal-Wallis tests were used to compare median untransformed miR levels 
according to nominal variables. 
 
Logistic regression models 
Conditional logistic regression models for associations between log2-transformed miR 
expression level and PDAC risk [where odds ratios (OR) represent relative risk per doubling 
of miR expression level] were conditioned on matching variables and adjusted for age at 
recruitment (years), smoking intensity (never, current 1-15 cig/d, current 16-25 cig/d, current 
26+ cig/d, former quit ≤10 yr, former quit 11-20 yr, former quit 20+ yr, and current users of 
non-cigarette tobacco products) or smoking status (never, former, current), baseline alcohol 
intake (g/day), education (none, primary, technical/professional, secondary, 
university/graduate school), BMI (kg/m
2
), and physical activity using the Cambridge index 
(inactive, moderately inactive, moderately active, and active)(33). Due to sample size 
constraints, conditional logistic regression models that were stratified by the follow-up time 
between blood collection and PDAC diagnosis were adjusted for age, smoking status, and 
alcohol intake only. 
 
miR score and interactions 
A miR score was created for each participant by summing each miR (except miR-21-3p 
which had similar expression levels between cases and controls) that was over-expressed 
above the 3
rd
 quartile (75
th
 percentile) in all 225 controls combined (range: 0-7). Participants 
with scores of 6-7 (the highest category) were combined due to small sample size. In 
exploratory analyses, two-fold interactions between each miR were evaluated by categorizing 
each miR as a dichotomous variable or in quartiles (using cutpoints based on the distribution 
in controls). Joint ORs were estimated for PDAC risk and pair-wise over-expression of miRs. 
Statistical significance of potential interactions was evaluated using a likelihood ratio test 
(LRT). 
 
Receiver operating characteristic (ROC) curves 
Predictive performance was assessed with respect to the ability of each miR and the miR 
score to discriminate between PDAC cases and controls using the ROC curve which evaluates 
the true positive rate (sensitivity) on the y-axis and the false positive rate (1-specificity) on the 
x-axis, with excellent accuracy defined as AUC > 0.90. Predictive performance for each miR 
was evaluated based on unconditional logistic regression models adjusted for matching 
factors, smoking status, and alcohol intake at baseline (34). Models for the miR score were 
additionally adjusted for BMI. To perform the ROC curve and to assess AUC, functions 
prediction and performance from the ROCR R package were used; to assess the 95% 
confidence intervals for the AUC, function ci.cvAUC implemented in the cvAUC R package 
was used. All statistical analyses were performed using SAS v.9.4 (Cary, NC, USA) and R 
v.3.2.5. 
 
 7 
RESULTS 
The median follow-up time between blood collection and PDAC diagnosis in the 225 cases 
was 7.85 yr (range: 10.86 yr; inter-quartile range: 4.22-9.47 yr). Correlation coefficients (rs) 
among the eight miRs ranged from 0.09 to 0.6 in control participants (P-values <0.0001 to 
0.18) with the strongest correlation between miR-10b and miR-212, and the weakest between 
miR-10b and miR-106b (Supplementary Table S4). There was little evidence for correlation 
between miR expression levels and age at recruitment (rs range -0.037 to 0.057, P-values 0.39 
to 0.95), except for miR-10b (rs 0.13, P-value 0.049). There was no evidence for correlations 
between the eight miRs and smoking intensity (correlation range -0.01 to 0.06, P-values 0.13 
to 0.89), or BMI (correlation range -0.0003 to 0.037, P-values 0.54 to 0.99). Individual miR 
expression levels did not significantly differ by sex (all Wilcoxon rank-sum test P-values 
>0.26).  Only miR-10b was weakly correlated with baseline alcohol intake (correlation 
coefficient 0.16, P-value 0.017), while the remaining miRs were not (correlation range -0.041 
to 0.12, P-values 0.069 to 0.79). None of the miRs was significantly associated with physical 
activity level (Kruskal-Wallis test P-values 0.06 to 0.8), or education level (Kruskal-Wallis 
test P-values 0.09 to 0.7).  
 
Comparison of expression levels for each miR between patients subsequently diagnosed with 
localized PDAC (n=13) vs. metastatic PDAC (n=96) did not show any significant differences 
(all P-values > 0.18; 116 cases had missing data on stage); however, the possibility that some 
patients with suspected localized PDAC already had micro-metastases cannot be excluded. 
Nine cases and 9 controls reported having had a history of diabetes at baseline (16 cases and 5 
controls were missing data on diabetes). Median relative expression was statistically 
significantly lower in diabetics vs. non-diabetics for miR-155 (cases: 0.43 vs. 0.75, P-
value=0.016; controls: 0.29 vs. 0.72, P-value=0.024), and miR-21-5p (controls: 1.07 vs. 1.11,  
P-value=0.029). Because of the low number of participants who reported a positive history of 
diabetes at baseline, this covariate was not included in conditional logistic regression models. 
 
Levels for each miR were compared between cases and controls according to the follow-up 
time between blood collection and PDAC diagnosis in the index cases (Figure 1). For the 
shortest follow-up times (≤2 yr), miR-10b, miR-21-5p, miR-30c, and miR-106b were 
statistically significantly higher in cases than their matched controls (Figure 1 and Table 1). 
For longer follow-up times (>5-8 yr and >8 yr), miR-10a, miR-10b, miR-30c, and miR-106b 
were statistically significantly higher in cases than controls. Overall, for longer follow-up 
times (>8 yr), and for all 225 cases and 225 matched controls (≤12 yr), the most consistent 
and statistically significant differences were observed for miR-10a, miR-10b, and miR-30c 
(Figure 1 and Table 1). There was no evidence for longitudinal differences in miR expression 
levels among controls and among cases by follow-up time between blood collection and 
PDAC diagnosis (Kruskal-Wallis test P-values >0.6, data not in tables), except for miR-106b 
among cases (P-value =0.01); however, there was no clear monotonic trend between median 
miR-106b expression level and follow-up time, and data were relatively sparse, especially at 
shorter follow-up times. 
 
Multivariable-adjusted, conditional logistic regression models for the association between 
relative miR expression level and PDAC risk were evaluated for various overlapping follow-
up times (i.e., ≤2 yr, ≤5 yr, ≤8 yr, and ≤12 yr) between blood collection and PDAC diagnosis 
(Table 2). When evaluating all 225 cases and 225 matched controls (follow-up time ≤12 yr), 
ORs for the association between miR expression level (as continuous variables) and PDAC 
risk were statistically significant for six miRs (miR-10a, -10b, -21-5p, -30c, -155, and -212) 
(Table 2). When these associations were evaluated according to shorter follow-up times 
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between blood collection and PDAC diagnosis (≤2 yr, ≤5 yr, ≤8 yr) ORs remained elevated 
for miR-10b, miR-21-5p, and miR-30c. The magnitude of ORs was somewhat stronger with 
shorter follow-up times for miR-21-5p, and to a lesser extent for miR-30c (Table 2).   
 
Adjusted associations between miR expression levels and PDAC risk were also evaluated 
according to the non-overlapping follow-up times that were examined in Figure 1 and Table 1 
(>2-5 yr, >5-8 yr, and >8 yr). For follow-up times >2-5 yr (29 cases, 29 controls), due to 
small sample size, these estimates are not shown. For >5-8 yr (53 cases, 53 controls), positive 
associations were observed for miR-10b (1.76, 95% CI=1.05-2.96) and miR-30c (OR=2.01, 
95% CI=1.11-3.62). Finally, for longer follow-up times >8 yr (108 cases, 108 controls), 
positive associations were observed for miR-10a (OR=2.05, 95% CI=1.36-3.10), miR-10b 
(OR=2.52, 95% CI=1.62-3.92), miR-30c (OR=2.35, 95% CI=1.54-3.57), and miR-106b 
(OR=2.61, 95% CI=1.57-4.34). Associations for follow-up ≤2 yr were statistically significant 
for miR-10b, miR-21-5p, and miR-30c (listed in Table 2).  
 
Fully-adjusted conditional ORs for the association between a miR expression score and 
PDAC risk showed statistically significant evidence for higher risks with higher numbers of 
over-expressed miRs, as well as a monotonic dose-response trend (Table 3). Adjusted and un-
adjusted analyses of the miR score by shorter follow-up (≤8 yr, ≤5 yr) produced risk estimates 
that were unstable due to sparse data (not shown).  
 
Fully-adjusted, conditional logistic regression models for each miR analyzed in quintiles and 
as continuous variables showed monotonic dose-response trends for miR-10a, miR-10b, miR-
21-5p, and miR-30c (Supplementary Table S5). A single, mutually-adjusted, conditional 
logistic regression model including all 8 miRs and covariates was also evaluated, and showed 
higher PDAC risk with increasing over-expression of miR-10a, miR-10b, and miR-30c, but 
with less of a tendency for monotonic trends (Supplementary Table S5). 
 
In exploratory analyses, we evaluated joint ORs for 2-fold (miR-miR) interactions.  Although 
some joint effect ORs showed higher PDAC risk in individuals with two over-expressed miRs 
(e.g., miR-10b//miR-21-5p, and miR-10b//miR-30c) compared to individual with neither or 
only one over-expressed, none of the interactions showed evidence of statistical significance 
(all LRT P-values >0.10). Interactions at shorter follow-up times were not evaluated due to 
small sample sizes. 
 
The performance of each pre-diagnostic miR (and the miR score variable) as a test for 
discriminating PDAC cases from controls was evaluated using the AUC which compares the 
true positive rate (sensitivity) on the y-axis with the false positive rate (1-specificity) on the x-
axis (Figure 2).  For shorter follow-up time (≤5 yr), the highest AUCs were for miR-21-5p 
(0.79, 95% CI=0.71-0.87) and miR-30c (0.77, 95% CI=0.66-0.76) and the lowest was for 
miR-212 (AUC=0.73, 95% CI=0.65-0.82). The discriminatory performance (AUC) of each 
miR and the score dramatically improved when we evaluated shorter follow-up (≤8 yr, ≤5 yr) 
between blood collection and PDAC diagnosis (Figure 2).  Discriminatory performance for 
follow-up times ≤2 yr was also higher, but due to logistic model non-convergence (i.e., small 
sample size), these data are not shown. 
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DISCUSSION 
Our nested case-control study evaluated the relative expression of a targeted panel of eight 
microRNAs in plasma samples collected years before diagnosis with PDAC. In general, for 
longer follow-up times (which may represent tumors in earlier stages of tumorigenesis), we 
observed moderately strong, fully-adjusted positive associations between over-expression of 
miR-10a, miR-10b, miR-21-5p, miR-30c and PDAC risk. Overexpression of miR-155 and 
miR-212 showed weak, but statistically significant, associations with risk. For shorter follow-
up times (which may represent tumors in later stages of tumorigenesis), we observed stronger 
associations with over-expression of miR-10b, miR-21-5p, and miR-30c (with ORs for miR-
21-5p stronger in magnitude with shorter follow-up times). Consideration of a score created 
using seven miRs yielded suggestive evidence for a cumulative effect (monotonically 
increasing risk with each additional over-expressed miR). The ORs for miR expression level 
and PDAC risk in our study were similar (or stronger) in magnitude to ORs typically 
observed in epidemiologic studies of smoking and PDAC. 
 
The three miRs that gave the most consistent evidence for an association between over-
expression in plasma collected years before PDAC diagnosis and risk were: miR-21-5p, miR-
30c, and miR-10b.  AUCs at shorter follow-up time (≤5 yr) between blood collection and 
PDAC diagnosis were highest for miR-21-5p (0.79) and miR-30c (0.77). These results should 
be replicated in other epidemiological study settings to evaluate their potential use as 
biomarkers of PDAC risk. Both miR-10a and -10b have been implicated in PDAC 
pathobiology and along with miR-21 may contribute to PDAC’s propensity to metastasize 
(5;10;11;14;21). While it is not known whether miR-21-3p has a role in PDAC, this miR may 
contribute to cancer progression and cisplatin resistance (23;24). Moreover, miR-30c is 
upregulated by the EGF receptor (35) and may contribute to PDAC progression, whereas 
miR-106b and miR-212 target Rb (16;36), thereby potentially inducing loss of negative 
growth constraints. Finally, miR-155 is expressed in PDAC (17), but its role in this cancer 
remains to be delineated. Nonetheless, miR-155 has been shown to enhance cancer cell 
proliferation and angiogenesis, and is likely to have an important role in PDAC (37;38).  
 
It is well established that PDAC is a heterogeneous cancer, and recent studies suggest that 
there are 4 major molecular subtypes (39). However, there is no evidence that each of these 
different molecular subtypes is associated with a unique miRNA profile. Conversely, it is 
possible that the kinetics of miRNA expression occurs at different time-points in these 
subtypes. Moreover, while PDAC may develop and progress over 15 to 17 years prior to 
developing distant metastases (40), it is now appreciated that a subgroup of patients have 
much more rapid PDAC progression due to concurrent and rapid acquisition of mutations 
(41), which further complicates the delineation of specific time points for the appearance of 
diagnostic miRNAs in the circulation.  
 
Importantly, a patient who underwent total pancreatectomy and islet autotransplantation 
(TPIAT), meaning that he received an infusion of his own islets into the venous portal system, 
developed hepatic metastases 10 months following the infusion that were histologically 
confirmed to be metastatic PDAC (25). The patient’s pancreas that had been removed 9 
months earlier only had PanIN2 lesions, and pre-operative serum samples revealed elevated 
levels of miR-10b, -30c, and -106b in comparison with serum from four other patients with 
chronic pancreatitis who underwent TPIAT (25). The high levels of all three miRs normalized 
three days post-pancreatectomy. Together, these findings suggest that the elevated levels of 
these three miRs in the patient’s circulation derived from a pancreas harboring advanced 
PanIN lesions (25), underscoring the potential use of miR-10b, -30c, and -106b in early 
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PDAC diagnosis. Additional studies assaying miR levels in circulating exosomes should be 
carried out to further explore this possibility. Inasmuch as some PDAC may progress more 
rapidly than previously realized (41), it is possible that some miR biomarkers, such as miR-
21-5p, may only increase in the circulation a relatively short time (≤2 yr) prior to clinical 
presentation.  
 
To our knowledge, this is the first published evaluation of miR expression and subsequent 
pancreatic cancer risk in a prospective cohort study. In previous studies, blood- and tissue-
based miR expression signatures have been reported to differentiate various pancreatic lesions 
(precursor lesions, chronic pancreatitis, neuroendocrine tumors, and PDAC) from one 
another, and from normal tissue, but previous studies have been retrospective, limited in 
sample size, and the specific miRs evaluated and reported have not been consistent across 
studies [(22;26;27;42-44), as previously reviewed (45-47)].  
 
Although our analyses provide support for the hypothesis that the over-expression of miRs 
may help to distinguish some individuals who may be at a higher risk of eventually 
developing PDAC, based on area under the ROC curves, our miR biomarker results fall short 
of being considered “clinically useful” tests for early PDAC detection or diagnosis in the 
general population. As pointed out by Wentzensen and Wacholder (2013), “to achieve any 
meaningful risk stratification for a rare disease would require a biomarker test with very high 
specificity” (48). In the case of pancreatic cancer, a biomarker test that yields ORs of 
magnitude of approximately 100 or more would likely be needed to yield high enough 
specificity (>99.5%) for a test to be considered clinically useful (48;49).  
                                                       
Weaknesses of our study include limited information on stage of cancer at diagnosis and 
diabetes at baseline, the absence of information on pancreatitis and new-onset diabetes prior 
to diagnosis, lack of information on CA19-9 levels, and a limited sample size. We chose a 
targeted approach in evaluating eight highly promising miRs as biomarkers of PDAC risk. 
Clearly, there may be other known or as yet undiscovered miRs that may improve risk 
prediction, or that may be more appropriate as markers of PDAC prognosis and/or treatment 
response (50). Strengths of our study design include the collection of exposure data and blood 
samples in a well-defined cohort many years before pancreatic cancer diagnosis.  
 
Although our study has not yielded a clear biomarker for early PDAC diagnosis, it provides 
useful information with respect to PDAC risk stratification, and, therefore advances the 
concept that levels of circulating miRs may have the potential to be useful for diagnosing 
PDAC. Additional work needs to be done to find a set of biomarkers or biochemical tests that 
can reliably identify high-risk individuals in the general population before their tumors spread 
beyond the pancreas. The simultaneous consideration of multiple biomarker tests (low 
abundance mutations, proteins, over-expressed miRs) in biofluids (plasma, secretin-
stimulated pancreatic juice, saliva, etc.) and salient clinical information (e.g., family history, 
smoking history, recent onset diabetes, ABO blood group, and recent use of heartburn or acid 
reflux medications) could be one way forward (49;51).  Our data thus advocate for the 
constitution of a much larger cohort together with molecular and imaging studies. 
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FIGURE 1 – microRNA expression levels by case / control status, and by follow-up time 
between blood collection and PDAC diagnosis.  
 
 
X-axis represents follow-up time between blood collection and PDAC diagnosis, and the Y-axis represents relative miRNA 
expression level. 
 
 
 
 
 
 
FIGURE 2 – ROC curves for each microRNA and the score variable in 225 PDAC cases and 
225 matched controls for different follow-up times (≤12 yr, ≤8 yr, ≤5 yr) 
 
 
ROC curves for separate unconditional logistic regression models for each log2-transformed miRNA, adjusted for age, 
smoking status, and alcohol intake at baseline. The miR score was additionally adjusted for BMI. TPR: True positive rate; 
FPR: False positive rate 
 
 
 
 
 
Supplementary FIGURE S1 – Specificity of miR-10a and miR-10b assays 
 
 
Increasing concentrations of miR-10a or miR-10b oligonucleotides (Sigma) were added (spiked in) to 100 μl of normal 
human plasma pre-cleared of cell debris by centrifugation at 1,000 x g for 10 minutes at 4C. RNA was isolated using Trizol 
LS (Life Technologies) and converted to cDNA using 10 ng RNA and the TaqMan MicroRNA Reverse Transcription Kit in 
conjunction with RNU6B (internal reference), miR-10a, and miR-10b TaqMan primers (Applied Biosystems). Converted 
cDNA was then subjected to qRT-PCR using the ViiA7 using TaqMan probes and TaqMan Fast Advanced Master Mix 
(Applied Biosystems). Levels for miR-10a and miR-10b were normalized to the internal reference (U6) to establish the ΔCt 
value, and then normalized to the ΔCt value from the control sample (without any added oligonucleotides, ΔΔCt). Expression 
levels were calculated using the 2-ΔΔCt method, documenting that the qRT-PCR assay readily differentiated between miR-10a 
and miR-10b over a wide concentration range of the respective miR. 
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